nodes	percent_of_prediction	percent_of_DWPC	metapath
Bismuth Subsalicylate—ALB—liver cancer	0.632	1	CbGaD
Bismuth Subsalicylate—TF—bile—liver cancer	0.0479	0.534	CbGeAlD
Bismuth Subsalicylate—TF—gall bladder—liver cancer	0.0133	0.148	CbGeAlD
Bismuth Subsalicylate—TF—embryo—liver cancer	0.00843	0.0939	CbGeAlD
Bismuth Subsalicylate—ALB—gall bladder—liver cancer	0.00692	0.0771	CbGeAlD
Bismuth Subsalicylate—TF—liver—liver cancer	0.0039	0.0434	CbGeAlD
Bismuth Subsalicylate—PTGS2—gall bladder—liver cancer	0.00377	0.042	CbGeAlD
Bismuth Subsalicylate—PTGS2—embryo—liver cancer	0.00239	0.0266	CbGeAlD
Bismuth Subsalicylate—Skin exfoliation—Sorafenib—liver cancer	0.00207	0.035	CcSEcCtD
Bismuth Subsalicylate—ALB—liver—liver cancer	0.00203	0.0226	CbGeAlD
Bismuth Subsalicylate—Hyponatraemia—Sorafenib—liver cancer	0.00158	0.0267	CcSEcCtD
Bismuth Subsalicylate—Venous thrombosis—Epirubicin—liver cancer	0.00148	0.0251	CcSEcCtD
Bismuth Subsalicylate—Abdominal pain upper—Sorafenib—liver cancer	0.00144	0.0243	CcSEcCtD
Bismuth Subsalicylate—Gastric ulcer—Epirubicin—liver cancer	0.00138	0.0233	CcSEcCtD
Bismuth Subsalicylate—Venous thrombosis—Doxorubicin—liver cancer	0.00137	0.0232	CcSEcCtD
Bismuth Subsalicylate—Abdominal discomfort—Sorafenib—liver cancer	0.0013	0.022	CcSEcCtD
Bismuth Subsalicylate—Gastric ulcer—Doxorubicin—liver cancer	0.00127	0.0216	CcSEcCtD
Bismuth Subsalicylate—Burning sensation—Epirubicin—liver cancer	0.00115	0.0195	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Sorafenib—liver cancer	0.00114	0.0193	CcSEcCtD
Bismuth Subsalicylate—Lung disorder—Epirubicin—liver cancer	0.00113	0.0191	CcSEcCtD
Bismuth Subsalicylate—PTGS2—liver—liver cancer	0.00111	0.0123	CbGeAlD
Bismuth Subsalicylate—Burning sensation—Doxorubicin—liver cancer	0.00107	0.018	CcSEcCtD
Bismuth Subsalicylate—Lung disorder—Doxorubicin—liver cancer	0.00105	0.0177	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Sorafenib—liver cancer	0.00103	0.0174	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Sorafenib—liver cancer	0.00101	0.0172	CcSEcCtD
Bismuth Subsalicylate—Stinging—Epirubicin—liver cancer	0.000988	0.0167	CcSEcCtD
Bismuth Subsalicylate—Erythema—Sorafenib—liver cancer	0.000947	0.016	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Sorafenib—liver cancer	0.000927	0.0157	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Epirubicin—liver cancer	0.000917	0.0155	CcSEcCtD
Bismuth Subsalicylate—Stinging—Doxorubicin—liver cancer	0.000914	0.0155	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Doxorubicin—liver cancer	0.000849	0.0144	CcSEcCtD
Bismuth Subsalicylate—Infection—Sorafenib—liver cancer	0.000768	0.013	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Epirubicin—liver cancer	0.000764	0.0129	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Sorafenib—liver cancer	0.000737	0.0125	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Epirubicin—liver cancer	0.000731	0.0124	CcSEcCtD
Bismuth Subsalicylate—Ecchymosis—Epirubicin—liver cancer	0.000724	0.0122	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Doxorubicin—liver cancer	0.000707	0.012	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Sorafenib—liver cancer	0.00068	0.0115	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Doxorubicin—liver cancer	0.000677	0.0115	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Epirubicin—liver cancer	0.000674	0.0114	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Sorafenib—liver cancer	0.000672	0.0114	CcSEcCtD
Bismuth Subsalicylate—Ecchymosis—Doxorubicin—liver cancer	0.00067	0.0113	CcSEcCtD
Bismuth Subsalicylate—Pain—Sorafenib—liver cancer	0.000661	0.0112	CcSEcCtD
Bismuth Subsalicylate—Constipation—Sorafenib—liver cancer	0.000661	0.0112	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Doxorubicin—liver cancer	0.000624	0.0106	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Sorafenib—liver cancer	0.000614	0.0104	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Sorafenib—liver cancer	0.000611	0.0103	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Epirubicin—liver cancer	0.000593	0.01	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Epirubicin—liver cancer	0.000583	0.00987	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Doxorubicin—liver cancer	0.000549	0.00928	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Sorafenib—liver cancer	0.000547	0.00925	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Doxorubicin—liver cancer	0.00054	0.00914	CcSEcCtD
Bismuth Subsalicylate—Abdominal pain upper—Epirubicin—liver cancer	0.000531	0.00898	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Sorafenib—liver cancer	0.000529	0.00895	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Sorafenib—liver cancer	0.000511	0.00865	CcSEcCtD
Bismuth Subsalicylate—Asthma—Epirubicin—liver cancer	0.000502	0.0085	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Sorafenib—liver cancer	0.000491	0.00831	CcSEcCtD
Bismuth Subsalicylate—Abdominal pain upper—Doxorubicin—liver cancer	0.000491	0.00831	CcSEcCtD
Bismuth Subsalicylate—Rash—Sorafenib—liver cancer	0.000487	0.00825	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Sorafenib—liver cancer	0.000487	0.00824	CcSEcCtD
Bismuth Subsalicylate—Headache—Sorafenib—liver cancer	0.000484	0.00819	CcSEcCtD
Bismuth Subsalicylate—Asthma—Doxorubicin—liver cancer	0.000465	0.00786	CcSEcCtD
Bismuth Subsalicylate—Nausea—Sorafenib—liver cancer	0.000459	0.00777	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Epirubicin—liver cancer	0.000457	0.00773	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Epirubicin—liver cancer	0.000448	0.00758	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Doxorubicin—liver cancer	0.000423	0.00716	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Epirubicin—liver cancer	0.000422	0.00715	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Doxorubicin—liver cancer	0.000414	0.00701	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Epirubicin—liver cancer	0.000402	0.0068	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Doxorubicin—liver cancer	0.000391	0.00661	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Epirubicin—liver cancer	0.00038	0.00643	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Epirubicin—liver cancer	0.000375	0.00634	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Doxorubicin—liver cancer	0.000372	0.00629	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Doxorubicin—liver cancer	0.000352	0.00595	CcSEcCtD
Bismuth Subsalicylate—Erythema—Epirubicin—liver cancer	0.00035	0.00592	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Doxorubicin—liver cancer	0.000347	0.00587	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Epirubicin—liver cancer	0.000343	0.0058	CcSEcCtD
Bismuth Subsalicylate—Erythema—Doxorubicin—liver cancer	0.000324	0.00548	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Doxorubicin—liver cancer	0.000317	0.00537	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Epirubicin—liver cancer	0.000288	0.00487	CcSEcCtD
Bismuth Subsalicylate—Oedema—Epirubicin—liver cancer	0.000286	0.00483	CcSEcCtD
Bismuth Subsalicylate—Infection—Epirubicin—liver cancer	0.000284	0.0048	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Epirubicin—liver cancer	0.000272	0.00461	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Doxorubicin—liver cancer	0.000266	0.00451	CcSEcCtD
Bismuth Subsalicylate—Oedema—Doxorubicin—liver cancer	0.000264	0.00447	CcSEcCtD
Bismuth Subsalicylate—Infection—Doxorubicin—liver cancer	0.000263	0.00444	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Epirubicin—liver cancer	0.000254	0.0043	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Doxorubicin—liver cancer	0.000252	0.00426	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Epirubicin—liver cancer	0.000251	0.00425	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Epirubicin—liver cancer	0.000248	0.0042	CcSEcCtD
Bismuth Subsalicylate—Constipation—Epirubicin—liver cancer	0.000244	0.00413	CcSEcCtD
Bismuth Subsalicylate—Pain—Epirubicin—liver cancer	0.000244	0.00413	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Epirubicin—liver cancer	0.000235	0.00398	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Doxorubicin—liver cancer	0.000235	0.00398	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Doxorubicin—liver cancer	0.000233	0.00394	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Doxorubicin—liver cancer	0.00023	0.00389	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Epirubicin—liver cancer	0.000227	0.00384	CcSEcCtD
Bismuth Subsalicylate—Pain—Doxorubicin—liver cancer	0.000226	0.00382	CcSEcCtD
Bismuth Subsalicylate—Constipation—Doxorubicin—liver cancer	0.000226	0.00382	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Epirubicin—liver cancer	0.000226	0.00382	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Doxorubicin—liver cancer	0.000218	0.00369	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Doxorubicin—liver cancer	0.00021	0.00355	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Doxorubicin—liver cancer	0.000209	0.00354	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Epirubicin—liver cancer	0.000202	0.00342	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Epirubicin—liver cancer	0.000195	0.00331	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Epirubicin—liver cancer	0.000189	0.0032	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Doxorubicin—liver cancer	0.000187	0.00316	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Epirubicin—liver cancer	0.000182	0.00307	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Doxorubicin—liver cancer	0.000181	0.00306	CcSEcCtD
Bismuth Subsalicylate—Rash—Epirubicin—liver cancer	0.00018	0.00305	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Epirubicin—liver cancer	0.00018	0.00304	CcSEcCtD
Bismuth Subsalicylate—Headache—Epirubicin—liver cancer	0.000179	0.00303	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Doxorubicin—liver cancer	0.000175	0.00296	CcSEcCtD
Bismuth Subsalicylate—Nausea—Epirubicin—liver cancer	0.00017	0.00287	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Doxorubicin—liver cancer	0.000168	0.00284	CcSEcCtD
Bismuth Subsalicylate—Rash—Doxorubicin—liver cancer	0.000167	0.00282	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Doxorubicin—liver cancer	0.000166	0.00282	CcSEcCtD
Bismuth Subsalicylate—Headache—Doxorubicin—liver cancer	0.000166	0.0028	CcSEcCtD
Bismuth Subsalicylate—Nausea—Doxorubicin—liver cancer	0.000157	0.00266	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK14—liver cancer	0.000122	0.000556	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—MYC—liver cancer	0.00012	0.000547	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—liver cancer	0.00012	0.000545	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CDKN1B—liver cancer	0.00012	0.000545	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—NR1H4—liver cancer	0.000118	0.00054	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.000118	0.000536	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—UGDH—liver cancer	0.000117	0.000535	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CASP3—liver cancer	0.000117	0.000534	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—KRAS—liver cancer	0.000117	0.000533	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—IL2—liver cancer	0.000117	0.000533	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—IGF2—liver cancer	0.000116	0.000529	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CCND1—liver cancer	0.000114	0.000519	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—APC—liver cancer	0.000113	0.000515	CbGpPWpGaD
Bismuth Subsalicylate—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—liver cancer	0.000113	0.000515	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—KRAS—liver cancer	0.000111	0.000505	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—MMP9—liver cancer	0.000111	0.000504	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—EPT1—liver cancer	0.00011	0.000503	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet degranulation—VEGFA—liver cancer	0.00011	0.0005	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—TNF—liver cancer	0.00011	0.0005	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—HGF—liver cancer	0.00011	0.000499	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—IL6—liver cancer	0.00011	0.000499	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Vitamin B12 Metabolism—IL6—liver cancer	0.000109	0.000496	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—CSF2—liver cancer	0.000108	0.000494	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—TNF—liver cancer	0.000108	0.000491	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—PIK3CA—liver cancer	0.000108	0.00049	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—TAT—liver cancer	0.000105	0.000477	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—liver cancer	0.000105	0.000476	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—TP53—liver cancer	0.000104	0.000474	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.000103	0.000469	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet degranulation—TGFB1—liver cancer	0.000101	0.000459	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—HRAS—liver cancer	9.95e-05	0.000453	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—GGT1—liver cancer	9.7e-05	0.000442	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—TP53—liver cancer	9.67e-05	0.000441	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—liver cancer	9.6e-05	0.000437	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—SERPINA1—liver cancer	9.59e-05	0.000437	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	9.53e-05	0.000434	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—UGDH—liver cancer	9.5e-05	0.000433	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—HRAS—liver cancer	9.43e-05	0.00043	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—MYC—liver cancer	9.15e-05	0.000417	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—TGFB1—liver cancer	9.12e-05	0.000416	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GLUL—liver cancer	8.96e-05	0.000408	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CPT1B—liver cancer	8.96e-05	0.000408	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—EPT1—liver cancer	8.93e-05	0.000407	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	8.87e-05	0.000404	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—IL6—liver cancer	8.85e-05	0.000403	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—AKT1—liver cancer	8.79e-05	0.0004	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—MAPK14—liver cancer	8.78e-05	0.0004	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—TNF—liver cancer	8.72e-05	0.000397	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—IL6—liver cancer	8.69e-05	0.000396	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—NR1H4—liver cancer	8.64e-05	0.000394	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—TNF—liver cancer	8.52e-05	0.000388	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—F2—liver cancer	8.51e-05	0.000388	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GSTA3—liver cancer	8.49e-05	0.000387	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—LTF—liver cancer	8.49e-05	0.000387	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—TAT—liver cancer	8.47e-05	0.000386	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	8.33e-05	0.000379	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—PIK3CG—liver cancer	8.14e-05	0.000371	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	8.13e-05	0.00037	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	7.97e-05	0.000363	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GSTA4—liver cancer	7.77e-05	0.000354	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	7.76e-05	0.000353	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	7.74e-05	0.000353	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—GGT1—liver cancer	7.7e-05	0.000351	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	7.68e-05	0.00035	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	7.59e-05	0.000346	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GSTA2—liver cancer	7.57e-05	0.000345	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—TP53—liver cancer	7.51e-05	0.000342	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	7.5e-05	0.000342	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	7.32e-05	0.000334	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GSTA1—liver cancer	7.3e-05	0.000333	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—NAT2—liver cancer	7.22e-05	0.000329	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—PIK3CD—liver cancer	7.16e-05	0.000326	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—IFNA1—liver cancer	7.14e-05	0.000325	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GLUL—liver cancer	7.11e-05	0.000324	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CPT1B—liver cancer	7.11e-05	0.000324	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—SERPINE1—liver cancer	7.08e-05	0.000322	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—IL6—liver cancer	7.03e-05	0.00032	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PPARA—liver cancer	6.95e-05	0.000316	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ALDOB—liver cancer	6.92e-05	0.000315	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—IL6—liver cancer	6.88e-05	0.000313	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—NR1H4—liver cancer	6.86e-05	0.000313	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	6.76e-05	0.000308	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GSTA3—liver cancer	6.74e-05	0.000307	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CRABP1—liver cancer	6.61e-05	0.000301	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—ALDOB—liver cancer	6.56e-05	0.000299	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—RAF1—liver cancer	6.39e-05	0.000291	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PRKCE—liver cancer	6.32e-05	0.000288	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—PIK3CB—liver cancer	6.24e-05	0.000284	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—GGT1—liver cancer	6.23e-05	0.000284	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	6.22e-05	0.000283	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	6.21e-05	0.000283	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GSTA4—liver cancer	6.17e-05	0.000281	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—CYCS—liver cancer	6.04e-05	0.000275	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	6.03e-05	0.000275	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GSTA2—liver cancer	6.01e-05	0.000274	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—ABL1—liver cancer	6.01e-05	0.000274	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—IGF2—liver cancer	5.98e-05	0.000273	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	5.95e-05	0.000271	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GSTA1—liver cancer	5.8e-05	0.000264	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	5.8e-05	0.000264	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—HPGDS—liver cancer	5.77e-05	0.000263	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CPT1B—liver cancer	5.75e-05	0.000262	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GLUL—liver cancer	5.75e-05	0.000262	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	5.75e-05	0.000262	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PPARG—liver cancer	5.74e-05	0.000262	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—NAT2—liver cancer	5.73e-05	0.000261	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—IL2—liver cancer	5.73e-05	0.000261	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—HGF—liver cancer	5.65e-05	0.000257	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—CSF2—liver cancer	5.59e-05	0.000255	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—NR1H4—liver cancer	5.55e-05	0.000253	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	5.51e-05	0.000251	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ALDOB—liver cancer	5.5e-05	0.00025	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GSTA3—liver cancer	5.46e-05	0.000249	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	5.28e-05	0.000241	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—HMOX1—liver cancer	5.25e-05	0.000239	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CRABP1—liver cancer	5.24e-05	0.000239	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	5.23e-05	0.000238	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—ADAM17—liver cancer	5.19e-05	0.000236	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—ALB—liver cancer	5.16e-05	0.000235	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PSMA4—liver cancer	5.15e-05	0.000234	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PSMD10—liver cancer	5.15e-05	0.000234	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	5.11e-05	0.000233	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GOT2—liver cancer	5.01e-05	0.000228	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GSTA4—liver cancer	4.99e-05	0.000227	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PSMD10—liver cancer	4.88e-05	0.000222	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PSMA4—liver cancer	4.88e-05	0.000222	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	4.88e-05	0.000222	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—VEGFA—liver cancer	4.87e-05	0.000222	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GSTA2—liver cancer	4.86e-05	0.000222	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—GOT2—liver cancer	4.75e-05	0.000216	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	4.72e-05	0.000215	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CYP2E1—liver cancer	4.71e-05	0.000214	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GSTA1—liver cancer	4.69e-05	0.000214	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—NAT2—liver cancer	4.64e-05	0.000211	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—HPGDS—liver cancer	4.58e-05	0.000209	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	4.56e-05	0.000208	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	4.56e-05	0.000208	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—MAPK14—liver cancer	4.52e-05	0.000206	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—TGFB1—liver cancer	4.47e-05	0.000204	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PPARA—liver cancer	4.46e-05	0.000203	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ALDOB—liver cancer	4.45e-05	0.000203	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CYCS—liver cancer	4.4e-05	0.000201	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—F2—liver cancer	4.38e-05	0.0002	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GOT1—liver cancer	4.32e-05	0.000197	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GGT1—liver cancer	4.32e-05	0.000197	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	4.31e-05	0.000197	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CRABP1—liver cancer	4.24e-05	0.000193	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—PPARA—liver cancer	4.24e-05	0.000193	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PIK3CG—liver cancer	4.2e-05	0.000191	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	4.15e-05	0.000189	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—ALB—liver cancer	4.1e-05	0.000187	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—GOT1—liver cancer	4.1e-05	0.000187	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PSMA4—liver cancer	4.09e-05	0.000186	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PSMD10—liver cancer	4.09e-05	0.000186	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GOT2—liver cancer	3.97e-05	0.000181	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GSTP1—liver cancer	3.88e-05	0.000177	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—HMOX1—liver cancer	3.83e-05	0.000174	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	3.82e-05	0.000174	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—PIK3CA—liver cancer	3.8e-05	0.000173	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PRKCE—liver cancer	3.78e-05	0.000172	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CYP2E1—liver cancer	3.74e-05	0.00017	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—HPGDS—liver cancer	3.71e-05	0.000169	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PIK3CD—liver cancer	3.69e-05	0.000168	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PPARG—liver cancer	3.69e-05	0.000168	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—SERPINE1—liver cancer	3.65e-05	0.000166	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	3.62e-05	0.000165	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GSTM1—liver cancer	3.57e-05	0.000163	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CYCS—liver cancer	3.5e-05	0.000159	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GOT1—liver cancer	3.43e-05	0.000156	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GGT1—liver cancer	3.43e-05	0.000156	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CYP1A1—liver cancer	3.38e-05	0.000154	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	3.36e-05	0.000153	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PSMA4—liver cancer	3.31e-05	0.000151	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PSMD10—liver cancer	3.31e-05	0.000151	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—H2AFX—liver cancer	3.3e-05	0.00015	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—RAF1—liver cancer	3.29e-05	0.00015	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GOT2—liver cancer	3.22e-05	0.000146	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PIK3CB—liver cancer	3.22e-05	0.000146	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—MTHFR—liver cancer	3.15e-05	0.000144	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—AKT1—liver cancer	3.11e-05	0.000142	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PPARA—liver cancer	3.09e-05	0.000141	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GSTP1—liver cancer	3.08e-05	0.00014	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—HMOX1—liver cancer	3.04e-05	0.000138	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CYP2E1—liver cancer	3.02e-05	0.000138	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MTHFR—liver cancer	2.99e-05	0.000136	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—TERT—liver cancer	2.98e-05	0.000136	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—IL2—liver cancer	2.95e-05	0.000135	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	2.93e-05	0.000133	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—RAF1—liver cancer	2.85e-05	0.00013	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GSTM1—liver cancer	2.83e-05	0.000129	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CYCS—liver cancer	2.83e-05	0.000129	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.78e-05	0.000127	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GGT1—liver cancer	2.78e-05	0.000126	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GOT1—liver cancer	2.78e-05	0.000126	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CYP1A1—liver cancer	2.68e-05	0.000122	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PIK3CG—liver cancer	2.65e-05	0.000121	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PPARG—liver cancer	2.56e-05	0.000116	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—APC—liver cancer	2.51e-05	0.000114	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—VEGFA—liver cancer	2.51e-05	0.000114	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—MTHFR—liver cancer	2.5e-05	0.000114	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GSTP1—liver cancer	2.49e-05	0.000114	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—HMOX1—liver cancer	2.46e-05	0.000112	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PPARA—liver cancer	2.46e-05	0.000112	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—BRAF—liver cancer	2.36e-05	0.000108	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PIK3CD—liver cancer	2.33e-05	0.000106	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—TGFB1—liver cancer	2.3e-05	0.000105	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ALB—liver cancer	2.3e-05	0.000105	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GSTM1—liver cancer	2.29e-05	0.000104	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PIK3CD—liver cancer	2.21e-05	0.000101	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.21e-05	0.0001	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—SERPINE1—liver cancer	2.18e-05	9.95e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CYP1A1—liver cancer	2.17e-05	9.9e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—KRAS—liver cancer	2.13e-05	9.72e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIK3CG—liver cancer	2.1e-05	9.58e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PIK3CB—liver cancer	2.03e-05	9.25e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PPARG—liver cancer	2.03e-05	9.25e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—MTHFR—liver cancer	2.02e-05	9.23e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PPARA—liver cancer	1.99e-05	9.05e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—RAF1—liver cancer	1.97e-05	8.98e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PIK3CA—liver cancer	1.96e-05	8.93e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MTOR—liver cancer	1.92e-05	8.77e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PIK3CB—liver cancer	1.92e-05	8.77e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—TP53—liver cancer	1.9e-05	8.64e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIK3CD—liver cancer	1.85e-05	8.42e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ALB—liver cancer	1.82e-05	8.31e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—HRAS—liver cancer	1.81e-05	8.26e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CDKN1B—liver cancer	1.81e-05	8.23e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.78e-05	8.13e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CTNNB1—liver cancer	1.71e-05	7.77e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIK3CG—liver cancer	1.7e-05	7.75e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CDKN1A—liver cancer	1.67e-05	7.59e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PPARG—liver cancer	1.64e-05	7.48e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIK3CB—liver cancer	1.61e-05	7.34e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—AKT1—liver cancer	1.6e-05	7.29e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIK3CD—liver cancer	1.5e-05	6.81e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—STAT3—liver cancer	1.49e-05	6.77e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MYC—liver cancer	1.38e-05	6.29e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—TGFB1—liver cancer	1.38e-05	6.28e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIK3CB—liver cancer	1.3e-05	5.94e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—KRAS—liver cancer	1.28e-05	5.82e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PIK3CA—liver cancer	1.24e-05	5.64e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PIK3CA—liver cancer	1.17e-05	5.34e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HRAS—liver cancer	1.09e-05	4.94e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—IL6—liver cancer	1.04e-05	4.73e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—AKT1—liver cancer	1.01e-05	4.61e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIK3CA—liver cancer	9.82e-06	4.48e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—AKT1—liver cancer	9.58e-06	4.37e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—AKT1—liver cancer	8.02e-06	3.66e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIK3CA—liver cancer	7.95e-06	3.62e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—AKT1—liver cancer	6.49e-06	2.96e-05	CbGpPWpGaD
